HP
SLXNW

Hartree Partners’s Silexion Therapeutics Warrant SLXNW Stock Holding History

Hartree Partners’s Portfolio SLXNW Stock Details SLXNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-182,355
Closed -$7.29K – 101
2025
Q3 		$7.29K Buy
+182,355
New +$6.4K ﹤0.01% 77

Other funds holding SLXNW

OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
SBLIC
Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return

Hartree Partners's SLXNW Position: Q3 2025 in Review

Hartree Partners sold out of Silexion Therapeutics Warrant (SLXNW) in Q3 2025, closing a stake of 182,355 shares — an estimated $6.4K sold.

Hartree Partners first reported a position in SLXNW in Q3 2024 and held it in 4 quarters. The position peaked at $14.6K in Q1 2025. 22 funds tracked by Wall St. Rank hold SLXNW as of Q3 2025.

  • Hartree Partners reported no remaining Silexion Therapeutics Warrant position as of Q3 2025 after selling out during the quarter.
  • Hartree Partners sold 182,355 Silexion Therapeutics Warrant shares in Q3 2025, an estimated $6.4K.
  • Hartree Partners first reported a position in Silexion Therapeutics Warrant in Q3 2024 and held it in 4 quarters.
  • Hartree Partners's Silexion Therapeutics Warrant position peaked at $14.6K in Q1 2025.
  • 22 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q3 2025.

Based on Hartree Partners's 13F filing for Q3 2025, filed 13 Nov 2025.